PMID 25044103 2014 Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.
rs121913530 in
KRAS gene and
Colorectal Neoplasms
PMID 21228335 2011 Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
PMID 20921465 2010 Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
PMID 19114683 2009 Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
PMID 19679400 2009 Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
PMID 18316791 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
PMID 16618717 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
PMID 20921462 2010 Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
PMID 22722830 2012 Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
PMID 16361624 2005 Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
PMID 23182985 2013 Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
rs121913530 in
KRAS gene and
Juvenile Myelomonocytic Leukemia
PMID 17332249 2007 Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
rs121913530 in
KRAS gene and
Non-Small Cell Lung Carcinoma
PMID 12460918 2002 BRAF and RAS mutations in human lung cancer and melanoma.
PMID 18794081 2008 Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
PMID 19358724 2009 KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
PMID 18594010 2008 EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
PMID 15696205 2005 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
PMID 17704260 2007 Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
rs121913530 in
KRAS gene and
Stomach Carcinoma
PMID 14534542 2003 BRAF and KRAS mutations in stomach cancer.
PMID 3034404 1987 Activated c-Ha-ras oncogene with a guanine to thymine transversion at the twelfth codon in a human stomach cancer cell line.
PMID 7773929 1995 Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases.
rs121913530 in
KRAS gene and
Thyroid Neoplasm
PMID 17384584 2007 Hyperactive Ras in developmental disorders and cancer.
PMID 19773371 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
PMID 19255327 2009 Phase II trial of sorafenib in metastatic thyroid cancer.